리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 07월
페이지 정보:영문 189 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 감마 나이프 시장은 2030년까지 4억 390만 달러에 달할 전망
2024년에 3억 1,080만 달러로 추정되는 세계의 감마 나이프 시장은 분석 기간인 2024-2030년에 CAGR 4.5%로 성장하며, 2030년에는 4억 390만 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 악성 종양은 CAGR 4.7%를 기록하며, 분석 기간 종료시에는 2억 2,110만 달러에 달할 것으로 예측됩니다. 양성 종양 부문의 성장률은 분석 기간 중 CAGR 4.4%로 추정됩니다.
미국 시장은 8,220만 달러로 추정, 중국은 CAGR 6.9%로 성장 예측
미국의 감마 나이프 시장은 2024년에 8,220만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 8,730만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 6.9%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.9%와 3.7%로 예측됩니다. 유럽에서는 독일이 CAGR 3.4%로 성장할 것으로 예측됩니다.
세계의 감마 나이프 시장 - 정의, 주요 동향과 촉진요인 정리
감마나이프란 무엇이며, 왜 현대 신경외과에서 중요한가?
감마나이프는 정위적 방사선 수술(SRS)의 일종으로 침습적 수술 없이 뇌종양, 혈관 기형, 기타 신경질환을 치료하는 데 사용됩니다. 그런데 왜 감마나이프가 신경외과에서 획기적인 치료법으로 여겨지는 이유는 무엇인가? 기존 수술과 달리 감마나이프는 감마선 집중 빔을 사용하여 뇌의 비정상적인 조직을 정확하게 조준하여 주변 건강한 조직을 손상시키지 않고 고선량의 방사선을 조사했습니다. 이 비침습적 수술은 정확성, 효과, 회복 시간 단축으로 유명하며 뇌 전이, 동정맥 기형(AVM), 삼차 신경통, 일부 양성 및 악성 뇌종양 등의 환자에게 선호되는 비침습적 수술입니다. 감마나이프는 물리적 절개가 필요하지 않기 때문에 감염, 출혈, 장기 회복과 같은 기존 뇌 수술의 위험을 최소화할 수 있습니다. 보다 최소 침습적인 치료에 대한 수요가 증가함에 따라 감마나이프 기술은 복잡한 뇌 질환을 정확하고 최소한의 부작용으로 치료할 수 있다는 점에서 현대 신경외과에서 점점 더 중요성이 커지고 있습니다.
기술 발전은 감마나이프 시장을 어떻게 형성하고 있는가?
기술 혁신은 감마나이프 시스템의 발전에 중요한 역할을 하고 있습니다. 한 가지 중요한 발전은 감마나이프 시스템과 MRI 및 CT 스캔과 같은 첨단 영상 기술을 감마나이프 시스템과 통합하여 치료 계획과 정확도를 향상시킨 것입니다. 이러한 영상 기술을 통해 뇌 병변의 위치를 보다 정확하게 파악할 수 있고, 방사선을 필요한 곳에 정확하게 조사하여 건강한 조직에 대한 손상을 최소화할 수 있습니다. 또한 실시간 영상처리와 3D 치료계획 소프트웨어의 도입으로 선량 조사의 정확도가 향상되어 뇌 전이 및 AVM과 같은 질환에 대해 보다 표적화된 치료가 가능해졌습니다.
또 다른 중요한 기술 혁신은 감마나이프 기술 자체의 진화입니다. 감마나이프 아이콘과 같은 감마나이프 시스템의 최신 버전은 첨단 모션 트래킹 및 고정 시스템을 탑재하여 프레임리스 치료가 가능합니다. 이를 통해 환자의 불편함을 줄이고 치료할 수 있는 병태의 폭을 넓혀줍니다. 또한 새로운 시스템은 분할 치료가 가능하여 필요에 따라 여러 번 나누어 방사선을 조사할 수 있으며, 더 큰 병변이나 복잡한 병변의 치료에도 유연하게 대응할 수 있습니다.
이러한 기술 발전으로 감마나이프 치료는 더욱 안전하고, 편안하고, 효과적이며, 의료진이 보다 광범위한 신경질환에 대한 방사선 수술의 사용을 확대하는 데 도움이 되고 있습니다.
규제와 헬스케어 동향이 감마나이프 시장에 어떤 영향을 미치고 있는가?
감마나이프 시장 형성에 있으며, 규제 프레임워크와 헬스케어 동향은 어떤 역할을 하고 있는가? 미국 식품의약국(FDA)과 유럽의약품청(EMA)과 같은 규제기관은 감마나이프 기술의 안전성과 유효성을 보장하는 데 중요한 역할을 하고 있습니다. 엄격한 규제 기준은 감마나이프 시스템과 같은 의료기기의 승인 및 사용을 유도하여 이러한 치료가 안전 요건을 충족하고 일관된 고품질 치료를 제공할 수 있도록 보장합니다. 또한 의료 서비스 프로바이더는 방사선 안전 표준을 준수해야 하며, 이는 전 세계에서 정위적 방사선 수술의 사용이 확대됨에 따라 점점 더 중요해지고 있습니다.
가치 기반 의료에 대한 관심이 높아지면서 감마나이프 기술 채택에도 영향을 미치고 있습니다. 의료 시스템이 결과 기반 모델로 전환됨에 따라 감마나이프와 같이 정확도가 높고 부작용이 적으며 회복 시간이 짧은 치료법은 환자와 의료진 모두에게 더욱 매력적으로 다가오고 있습니다. 입원 기간과 재활 기간이 길어지는 기존 개복 수술에 비해 비침습적 수술의 비용 효율성이 높기 때문에 점점 더 많은 병원 및 클리닉이 감마나이프 기술에 투자하고 있습니다. 또한 최소침습적 치료에 대한 수요 증가로 인해 전 세계에서 정위적 방사선 수술센터가 확대되고 있으며, 특히 아시아태평양 및 라틴아메리카 등의 지역에서 성장하고 있습니다.
또한 전 세계에서 암 발병률 증가, 특히 뇌 전이 증가로 인해 감마나이프와 같은 첨단 방사선 수술 툴에 대한 수요가 증가할 것으로 예측됩니다. 이러한 규제 및 헬스케어 동향은 감마나이프가 복잡한 뇌 질환을 치료하기 위한 안전하고 효과적이며 경제적으로 실행 가능한 선택이 될 수 있도록 보장하며 시장을 형성하고 있습니다.
감마나이프 시장 성장의 주요 촉진요인은?
감마나이프 시장의 성장은 뇌 질환의 유병률 증가, 방사선 수술 기술의 발전, 최소침습적 치료 옵션에 대한 수요 증가 등 몇 가지 중요한 요인에 의해 이루어지고 있습니다. 주요 촉진요인 중 하나는 뇌종양, 혈관 기형, 신경 장애의 유병률 증가로 인해 정밀하고 효과적인 치료법에 대한 요구가 증가하고 있습니다. 감마나이프 방사선 수술은 최소한의 위험으로 이러한 질환을 치료할 수 있는 것으로 널리 알려져 있으며, 기존 수술이 적합하지 않은 환자들에게 선호되는 치료법입니다. 감마나이프 치료의 정확성과 안전성을 향상시킨 영상 및 방사선 기술의 발전은 감마나이프 치료의 큰 원동력이 되었습니다. 이러한 기술 혁신을 통해 의료진은 더 복잡한 환자를 치료하고, 환자 결과를 개선하며, 부작용을 줄일 수 있게 되었습니다. 또한 고령화 사회는 감마나이프 시장의 성장에 기여하고 있습니다. 고령 환자는 뇌 질환의 위험이 높은 경우가 많아 비침습적 치료법을 찾는 경향이 높기 때문입니다.
또한 환자와 의료 서비스 프로바이더는 빠른 회복과 합병증이 적은 치료를 원하므로 외래 치료에 대한 수요가 증가하고 있습니다. 감마나이프 치료는 일반적으로 하룻밤의 입원이 필요하지 않기 때문에 외래 환자들에게 매력적인 선택이 되고 있습니다. 감마나이프 센터가 전 세계에서, 특히 신흥 시장에서 점점 더 많은 의료 서비스 프로바이더들이 이 첨단 기술에 투자하면서 시장 확대에 더욱 박차를 가하고 있습니다. 비침습적 치료에 대한 수요 증가, 기술 발전, 신경질환의 부담 증가 등의 요인이 결합되어 감마 나이프 세계 시장은 강력한 성장세를 보이고 있으며, 감마나이프는 신경외과의 미래에서 중요한 툴로 자리매김하고 있습니다.
부문
적응증(악성 종양, 양성 종양, 혈관 장애, 기능 장애, 안질환)
조사 대상 기업의 예
Accuray, Inc.
Brainlab AG
Elekta AB
Elsan SAS
IBA Dosimetry GmbH
Mevion Medical Systems, Inc.
Panacea Medical Technologies Pvt. Ltd.
Sun Nuclear Corporation
Varian Medical Systems, Inc.
Zap Surgical Systems Inc.
AI 통합
Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Gamma Knife Market to Reach US$403.9 Million by 2030
The global market for Gamma Knife estimated at US$310.8 Million in the year 2024, is expected to reach US$403.9 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Malignant Tumors, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$221.1 Million by the end of the analysis period. Growth in the Benign Tumors segment is estimated at 4.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$82.2 Million While China is Forecast to Grow at 6.9% CAGR
The Gamma Knife market in the U.S. is estimated at US$82.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$87.3 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.
What Is Gamma Knife and Why Is It Important in Modern Neurosurgery?
Gamma Knife is a form of stereotactic radiosurgery (SRS) used to treat brain tumors, vascular malformations, and other neurological conditions without invasive surgery. But why is Gamma Knife considered a breakthrough in neurosurgery? Unlike traditional surgery, Gamma Knife uses focused beams of gamma radiation to precisely target abnormal tissue in the brain, delivering high doses of radiation without harming surrounding healthy tissue. This non-invasive procedure is known for its accuracy, effectiveness, and reduced recovery time, making it a preferred option for patients with conditions like brain metastases, arteriovenous malformations (AVMs), trigeminal neuralgia, and certain types of benign and malignant brain tumors. Since Gamma Knife does not require physical incisions, the risks associated with traditional brain surgery-such as infection, bleeding, and extended recovery-are minimized. As demand for less invasive treatments grows, Gamma Knife technology has become increasingly important in modern neurosurgery for its ability to treat complex brain conditions with precision and minimal side effects.
How Are Technological Advancements Shaping the Gamma Knife Market?
Technological innovations are playing a key role in advancing Gamma Knife systems. But how are these advancements improving the effectiveness and safety of the procedure? One major development is the integration of advanced imaging technologies, such as MRI and CT scans, with Gamma Knife systems to enhance treatment planning and accuracy. These imaging techniques allow for more precise localization of brain lesions, ensuring that radiation is delivered exactly where it is needed, minimizing damage to healthy tissue. The incorporation of real-time imaging and 3D treatment planning software has also improved the precision of dose delivery, enabling more targeted treatments for conditions like brain metastases and AVMs.
Another key innovation is the evolution of the Gamma Knife technology itself. The latest versions of Gamma Knife systems, such as the Gamma Knife Icon, feature advanced motion tracking and immobilization systems, allowing for frameless treatments. This reduces patient discomfort and expands the range of treatable conditions. Moreover, new systems offer the ability to deliver fractionated treatments, meaning that radiation can be delivered over multiple sessions if needed, providing more flexibility for treating larger or more complex lesions.
These technological advancements are making Gamma Knife treatments safer, more comfortable, and more effective, helping healthcare providers expand the use of radiosurgery for a broader range of neurological conditions.
How Are Regulations and Healthcare Trends Impacting the Gamma Knife Market?
What role do regulatory frameworks and healthcare trends play in shaping the Gamma Knife market? Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a critical role in ensuring the safety and efficacy of Gamma Knife technology. Strict regulatory standards guide the approval and use of medical devices like Gamma Knife systems, ensuring that these treatments meet safety requirements and deliver consistent, high-quality care. Additionally, healthcare providers must comply with radiation safety standards, which are becoming increasingly important as the use of stereotactic radiosurgery expands globally.
The growing trend toward value-based healthcare is also influencing the adoption of Gamma Knife technology. As healthcare systems shift toward outcomes-based models, treatments that offer high precision, reduced side effects, and shorter recovery times-such as Gamma Knife-are becoming more attractive to both patients and providers. The cost-effectiveness of non-invasive procedures, compared to traditional open surgery with longer hospitalization and rehabilitation periods, is encouraging more hospitals and clinics to invest in Gamma Knife technology. Moreover, the rising demand for minimally invasive treatments is driving the expansion of stereotactic radiosurgery centers globally, with particular growth in regions such as Asia-Pacific and Latin America.
Furthermore, as the global burden of cancer continues to rise, particularly with the increasing incidence of brain metastases, the need for advanced radiosurgical tools like Gamma Knife is expected to grow. These regulatory and healthcare trends are shaping the market by ensuring that Gamma Knife remains a safe, effective, and financially viable option for treating complex brain conditions.
What Are the Key Drivers Behind the Growth of the Gamma Knife Market?
The growth in the Gamma Knife market is driven by several key factors, including the increasing incidence of brain disorders, advancements in radiosurgical technology, and the growing demand for minimally invasive treatment options. One of the primary drivers is the rising prevalence of brain tumors, vascular malformations, and neurological disorders, which has increased the need for precise and effective treatment modalities. Gamma Knife radiosurgery is widely recognized for its ability to treat these conditions with minimal risk, making it a preferred choice for patients who are not candidates for traditional surgery. Another significant driver is the advancement in imaging and radiation technologies, which have enhanced the accuracy and safety of Gamma Knife treatments. These innovations allow healthcare providers to treat more complex cases, improve patient outcomes, and reduce side effects. Additionally, the aging global population is contributing to the growth of the Gamma Knife market, as elderly patients are often at higher risk for brain conditions and are more likely to seek non-invasive treatments.
The demand for outpatient procedures is also rising, as patients and healthcare providers seek treatments that offer faster recovery times and fewer complications. Gamma Knife treatments typically require no overnight hospital stay, making them an appealing option in outpatient settings. The growing availability of Gamma Knife centers worldwide, particularly in emerging markets, is further driving the expansion of the market as more healthcare providers invest in this cutting-edge technology. Together, these factors-rising demand for non-invasive treatments, technological advancements, and the increasing burden of neurological diseases-are driving robust growth in the global Gamma Knife market, positioning it as a key tool in the future of neurosurgery.
SCOPE OF STUDY:
The report analyzes the Gamma Knife market in terms of units by the following Segments, and Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
Accuray, Inc.
Brainlab AG
Elekta AB
Elsan SAS
IBA Dosimetry GmbH
Mevion Medical Systems, Inc.
Panacea Medical Technologies Pvt. Ltd.
Sun Nuclear Corporation
Varian Medical Systems, Inc.
Zap Surgical Systems Inc.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Global Economic Update
Gamma Knife - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Brain Tumors and Neurological Disorders Drives Demand for Gamma Knife Radiosurgery
Technological Advancements in Gamma Knife Systems Propel Growth in Precision Treatment for Complex Brain Conditions
Increasing Adoption of Non-Invasive Treatment Solutions Expands Market for Gamma Knife as a Preferred Alternative to Traditional Surgery
Growing Focus on Minimally Invasive Neurosurgery Fuels Demand for Gamma Knife in the Treatment of Brain Metastases and Arteriovenous Malformations (AVMs)
Rising Demand for Outpatient Treatment Options Strengthens the Business Case for Gamma Knife Radiosurgery Due to Shorter Recovery Times
Increasing Use of Gamma Knife for Treating Functional Disorders, Such as Trigeminal Neuralgia, Expands Clinical Applications
Technological Innovations in Imaging and Targeting Techniques Propel Growth in Real-Time Monitoring and Enhanced Treatment Accuracy
Rising Global Awareness of Stereotactic Radiosurgery (SRS) Strengthens Market Demand for Gamma Knife in Neurological and Oncological Treatments
Growing Emphasis on Reducing Side Effects and Enhancing Patient Outcomes Fuels Adoption of Gamma Knife for High-Precision Radiosurgery
Increasing Focus on Elderly Patients and Their Unique Treatment Needs Expands Market for Gamma Knife as a Safe and Effective Option
Technological Advancements in Motion Tracking and Immobilization Systems Support Growth in Frameless Gamma Knife Treatments
Rising Adoption of Gamma Knife in Pediatric Neurosurgery Expands Market for Non-Invasive Treatment of Pediatric Brain Disorders
Growing Focus on Value-Based Healthcare Drives Adoption of Gamma Knife as a Cost-Effective Alternative to Open Surgery
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 2: World Historic Review for Gamma Knife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 3: World 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Malignant Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 5: World Historic Review for Malignant Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 6: World 15-Year Perspective for Malignant Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Benign Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 8: World Historic Review for Benign Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 9: World 15-Year Perspective for Benign Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Vascular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 11: World Historic Review for Vascular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 12: World 15-Year Perspective for Vascular Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Functional Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 14: World Historic Review for Functional Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 15: World 15-Year Perspective for Functional Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Ocular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 17: World Historic Review for Ocular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 18: World 15-Year Perspective for Ocular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 19: World Gamma Knife Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
III. MARKET ANALYSIS
UNITED STATES
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 21: USA Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 22: USA 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 25: Canada 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
JAPAN
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 27: Japan Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 28: Japan 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
CHINA
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 29: China Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 30: China Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 31: China 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
EUROPE
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Gamma Knife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 34: Europe 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 35: Europe Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 36: Europe Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: Europe 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
FRANCE
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: France Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: France 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
GERMANY
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 41: Germany Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: Germany Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: Germany 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
ITALY
TABLE 44: Italy Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: Italy Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: Italy 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
UNITED KINGDOM
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 47: UK Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: UK Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: UK 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
SPAIN
TABLE 50: Spain Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Spain Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: Spain 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
RUSSIA
TABLE 53: Russia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Russia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: Russia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Rest of Europe Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: Rest of Europe 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Gamma Knife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: Asia-Pacific 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Asia-Pacific Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: Asia-Pacific 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
AUSTRALIA
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 65: Australia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Australia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: Australia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
INDIA
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 68: India Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: India Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: India 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 71: South Korea Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: South Korea Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: South Korea 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Rest of Asia-Pacific Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Rest of Asia-Pacific 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
LATIN AMERICA
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 77: Latin America Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 78: Latin America Historic Review for Gamma Knife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: Latin America 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 80: Latin America Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Latin America Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: Latin America 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 83: Argentina Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Argentina Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: Argentina 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
BRAZIL
TABLE 86: Brazil Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Brazil Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: Brazil 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
MEXICO
TABLE 89: Mexico Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: Mexico Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: Mexico 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of Latin America Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: Rest of Latin America 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
MIDDLE EAST
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 95: Middle East Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 96: Middle East Historic Review for Gamma Knife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: Middle East 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 98: Middle East Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Middle East Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Middle East 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
IRAN
TABLE 101: Iran Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Iran Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Iran 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
ISRAEL
TABLE 104: Israel Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Israel Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: Israel 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Saudi Arabia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Saudi Arabia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 110: UAE Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: UAE Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: UAE 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: Rest of Middle East Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: Rest of Middle East 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
AFRICA
Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 116: Africa Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: Africa Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: Africa 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030